Inhibition of Interleukin-17A, But Not Interleukin-17F, Signaling Lowers Blood Pressure, and Reduces End-Organ Inflammation in Angiotensin II–Induced Hypertension

JACC: Basic to Translational Science

Volumn 1, Issue 7, 2016, Pages 606-616

  Saleh, Mohamed A ^a,b   Norlander, Allison E ^c   Madhur, Meena S ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin II; gamma delta T cells; hypertension; interleukin 17A; interleukin 17F; interleukin 17RA receptor; T lymphocytes

Indexed keywords

EID: 85016124883     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2016.07.009     Document Type: Review

References (32)

1. 1 Harrison, D.G., Marvar, P.J., Titze, J.M., Vascular inflammatory cells in hypertension. Front Physio, 3, 2012, 128.
2. 2 McMaster, W.G., Kirabo, A., Madhur, M.S., Harrison, D.G., Inflammation, immunity, and hypertensive end-organ damage. Circ Res 116 (2015), 1022–1033.
3. 3 Madhur, M.S., Lob, H.E., McCann, L.A., et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55 (2010), 500–507.
4. 4 Nguyen, H., Chiasson, V.L., Chatterjee, P., Kopriva, S.E., Young, K.J., Mitchell, B.M., Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res 97 (2013), 696–704.
5. 5 Kamat, N.V., Thabet, S.R., Xiao, L., et al. Renal transporter activation during angiotensin-II hypertension is blunted in interferon-gamma-/- and interleukin-17A-/- mice. Hypertension 65 (2015), 569–576.
6. 6 Norlander, A.E., Saleh, M.A., Kamat, N.V., et al. Interleukin-17A regulates renal sodium transporters and renal injury in angiotensin II-induced hypertension. Hypertension 68 (2016), 167–174.
7. 7 Aggarwal, S., Gurney, A.L., IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 71 (2002), 1–8.
8. 8 Wright, J.F., Bennett, F., Li, B., et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol 181 (2008), 2799–2805.
9. 9 Beringer, A., Noack, M., Miossec, P., IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med 22 (2016), 230–241.
10. 10 Yang, X.O., Chang, S.H., Park, H., et al. Regulation of inflammatory responses by IL-17F. J Exp Med 205 (2008), 1063–1075.
11. 11 Xu, S., Cao, X., Interleukin-17 and its expanding biological functions. Cell Mol Immunol 7 (2010), 164–174.
12. 12 Ito, Y., Usui, T., Kobayashi, S., et al. Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum 60 (2009), 2294–2303.
13. 13 Roark, C.L., Simonian, P.L., Fontenot, A.P., Born, W.K., O'Brien, R.L., Gammadelta T cells: an important source of IL-17. Curr Opin Immunol 20 (2008), 353–357.
14. 14 Li, Y., Wu, Y., Zhang, C., et al. gammadeltaT Cell-derived interleukin-17A via an interleukin-1beta-dependent mechanism mediates cardiac injury and fibrosis in hypertension. Hypertension 64 (2014), 305–314.
15. 15 Wu, C., Yosef, N., Thalhamer, T., et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 496 (2013), 513–517.
16. 16 Kleinewietfeld, M., Manzel, A., Titze, J., et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496 (2013), 518–522.
17. 17 Chan, A.J., Alikhan, M.A., Odobasic, D., et al. Innate IL-17A-producing leukocytes promote acute kidney injury via inflammasome and Toll-like receptor activation. Am J Pathol 184 (2014), 1411–1418.
18. 18 Cheng, X., Taleb, S., Wang, J., et al. Inhibition of IL-17A in atherosclerosis. Atherosclerosis 215 (2011), 471–474.
19. 19 Amador, C.A., Barrientos, V., Pena, J., et al. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 63 (2014), 797–803.
20. 20 Madhur, M.S., Funt, S.A., Li, L., et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 31 (2011), 1565–1572.
21. 21 Saleh, M.A., McMaster, W.G., Wu, J., et al. Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation. J Clin Invest 125 (2015), 1189–1202.
22. 22 Shooshtari, P., Fortuno, E.S. 3rd, Blimkie, D., et al. Correlation analysis of intracellular and secreted cytokines via the generalized integrated mean fluorescence intensity. Cytometry A 77 (2010), 873–880.
23. 23 Branton, M.H., Kopp, J.B., TGF-beta and fibrosis. Microbes Infect 1 (1999), 1349–1365.
24. 24 Yao, W., Sun, Y., Wang, X., Niu, K., Elevated serum level of interleukin 17 in a population with prehypertension. J Clin Hypertens (Greenwich) 17 (2015), 770–774.
25. 25 Guzik, T.J., Mikolajczyk, T., In search of the T cell involved in hypertension and target organ damage. Hypertension 64 (2014), 224–226.
26. 26 Paust, H.J., Turner, J.E., Steinmetz, O.M., et al. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol 20 (2009), 969–979.
27. 27 Armstrong, A.W., Lin, S.W., Chambers, C.J., Sockolov, M.E., Chin, D.L., Psoriasis and hypertension severity: results from a case-control study. PLoS One, 6, 2011, e18227.
28. 28 Ernste, F.C., Sanchez-Menendez, M., Wilton, K.M., Crowson, C.S., Matteson, E.L., Maradit Kremers, H., Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 67 (2015), 1015–1021.
29. 29 Takeshita, J., Wang, S., Shin, D.B., et al. Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol 151 (2015), 161–169.
30. 30 Krebs, C.F., Lange, S., Niemann, G., et al. Deficiency of the interleukin 17/23 axis accelerates renal injury in mice with deoxycorticosterone acetate+angiotensin II-induced hypertension. Hypertension 63 (2014), 565–571.
31. 31 Mohamed, R., Jayakumar, C., Chen, F., et al. Low-dose IL-17 therapy prevents and reverses diabetic nephropathy, metabolic syndrome, and associated organ fibrosis. J Am Soc Nephrol 27 (2016), 745–765.
32. 32 Hamour, S., Gan, P.Y., Pepper, R., et al. Local IL-17 production exerts a protective role in murine experimental glomerulonephritis. PLoS One, 10, 2015, e0136238.